Evidence map›Paper›PMID 32326426›Full record

ArticleJournal of clinical medicine2020

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression.

Florence Carrouel, Maria Pia Conte, Julian Fisher, Lucio Souza Gonçalves, Claude Dussart, Juan Carlos Llodra, Denis Bourgeois

5 registry-linked trialsOpen access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 71 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 7 pooled it
12.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04352959 nacompletednot on this map

COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study

TypeinterventionalSponsorClaude Bernard UniversityRan2020 to 2020Enrolled176ConditionsCOVID19, Mouthwash, SalivaArmsmouthrinse with bêta-cyclodextrin and citrox, mouthrinse without bêta-cyclodextrin and citrox
NCT04584684 phase2terminatednot on this map

Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2020 to 2021Enrolled128ConditionsCovid19, Coronavirus Infection, SARS-CoV-2 InfectionArms0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide
NCT04721457 phase4completednot on this mapstarted 2021, after this paper: background citation

Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial

TypeinterventionalSponsorKing Abdulaziz UniversityRan2021 to 2021Enrolled90ConditionsSARS-CoV-2, COVID-19, Mouthwashes, Viral LoadArmsDistilled Water, 1% Povidone Iodine (PVP-I), 1.5% Hydrogen Peroxide (H2O2), 0.075% Cetylpyridinium Chloride (CPC), 0.1% Sodium Hypochlorite
NCT04748783 phase2terminatednot on this mapstarted 2021, after this paper: background citation

Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2021 to 2021Enrolled2ConditionsCOVID19, Coronavirus Infection, SARS CoV-2 InfectionArmsWater, Peroxyl, Periogard, Colgate Total Zero
NCT05178173 nacompletednot on this mapstarted 2022, after this paper: background citation

Antiviral Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)

TypeinterventionalSponsorUniversity of North Carolina, Chapel HillRan2022 to 2023Enrolled230ConditionsCOVID-19, Coronavirus Infection, SARS CoV 2 InfectionArmsPlacebo Comparator: Sterile Water, 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 7 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 5 countries.

Florence CarrouelUniversity Lyon 1, Laboratory "Health Systemic Process", EA4129, 69008 Lyon, France.
Maria Pia ConteSapienza University of Rome, Department of Public Health and Infectious Diseases, 00185 Rome, Italy.
Julian FisherTHEnet, Training for Health Equity Network, New York, NY 10023, USA.
Lucio Souza GonçalvesEstacio de Sá University, Faculty of Dentistry, Rio de Janeiro 22640-102, Brazil.
Claude DussartLyon Public Hospices, Central Pharmacy, EA4129, 69002 Lyon, France.
Juan Carlos LlodraUniversity of Granada, Department of Preventive and Community Dentistry, 18010 Granada, Spain.
Denis BourgeoisUniversity Lyon 1, Laboratory "Health Systemic Process", EA4129, 69008 Lyon, France.
Université Claude Bernard Lyon 1 · FREstácio (Brazil) · BRHealth Net · USHospices Civils de Lyon · FRSapienza University of Rome · ITUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression.

Indexed as

2019-nCoVCitroxCOVID-19microbiomemouthrinseoral cavitySARS-CoV-2viral loadβ-cyclodextrins

Identifiers

PMID32326426
PMCPMC7230644
OpenAlexW3015501930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.